Cargando…
SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
BACKGROUND: There is a need for validated and standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the coronavirus dis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717402/ https://www.ncbi.nlm.nih.gov/pubmed/33442555 http://dx.doi.org/10.1093/ofid/ofaa555 |
_version_ | 1783619309364314112 |
---|---|
author | Gundlapalli, Adi V Salerno, Reynolds M Brooks, John T Averhoff, Francisco Petersen, Lyle R McDonald, L Clifford Iademarco, Michael F |
author_facet | Gundlapalli, Adi V Salerno, Reynolds M Brooks, John T Averhoff, Francisco Petersen, Lyle R McDonald, L Clifford Iademarco, Michael F |
author_sort | Gundlapalli, Adi V |
collection | PubMed |
description | BACKGROUND: There is a need for validated and standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the coronavirus disease 2019 (COVID-19) pandemic response. METHODS: Literature searches were conducted to identify English language publications from peer-reviewed journals and preprints from January 2020 through November 6, 2020. Relevant publications were reviewed for mention of IgG or neutralization assays for SARS-CoV-2, or both, and the methods of reporting assay results. RESULTS: Quantitative SARS-CoV-2 IgG results have been reported from a limited number of studies; most studies used in-house laboratory-developed tests in limited settings, and only two semiquantitative tests have received US Food and Drug Administration (FDA) Emergency Use Authorization (EUA). As of November 6, 2020, there is only one SARS-CoV-2 neutralization assay with FDA EUA. Relatively few studies have attempted correlation of quantitative IgG titers with neutralization results to estimate surrogates of protection. The number of individuals tested is small compared with the magnitude of the pandemic, and persons tested are not representative of disproportionately affected populations. Methods of reporting quantitative results are not standardized to enable comparisons and meta-analyses. CONCLUSIONS: Lack of standardized SARS-CoV-2 quantitative IgG and neutralization assays precludes comparison of results from published studies. Interassay and interlaboratory validation and standardization of assays will support efforts to better understand antibody kinetics and longevity of humoral immune responses postillness, surrogates of immune protection, and vaccine immunogenicity and efficacy. Public–private partnerships could facilitate realization of these advances in the United States and worldwide. |
format | Online Article Text |
id | pubmed-7717402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77174022020-12-09 SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response Gundlapalli, Adi V Salerno, Reynolds M Brooks, John T Averhoff, Francisco Petersen, Lyle R McDonald, L Clifford Iademarco, Michael F Open Forum Infect Dis Review Article BACKGROUND: There is a need for validated and standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the coronavirus disease 2019 (COVID-19) pandemic response. METHODS: Literature searches were conducted to identify English language publications from peer-reviewed journals and preprints from January 2020 through November 6, 2020. Relevant publications were reviewed for mention of IgG or neutralization assays for SARS-CoV-2, or both, and the methods of reporting assay results. RESULTS: Quantitative SARS-CoV-2 IgG results have been reported from a limited number of studies; most studies used in-house laboratory-developed tests in limited settings, and only two semiquantitative tests have received US Food and Drug Administration (FDA) Emergency Use Authorization (EUA). As of November 6, 2020, there is only one SARS-CoV-2 neutralization assay with FDA EUA. Relatively few studies have attempted correlation of quantitative IgG titers with neutralization results to estimate surrogates of protection. The number of individuals tested is small compared with the magnitude of the pandemic, and persons tested are not representative of disproportionately affected populations. Methods of reporting quantitative results are not standardized to enable comparisons and meta-analyses. CONCLUSIONS: Lack of standardized SARS-CoV-2 quantitative IgG and neutralization assays precludes comparison of results from published studies. Interassay and interlaboratory validation and standardization of assays will support efforts to better understand antibody kinetics and longevity of humoral immune responses postillness, surrogates of immune protection, and vaccine immunogenicity and efficacy. Public–private partnerships could facilitate realization of these advances in the United States and worldwide. Oxford University Press 2020-11-17 /pmc/articles/PMC7717402/ /pubmed/33442555 http://dx.doi.org/10.1093/ofid/ofaa555 Text en Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020. http://www.nationalarchives.gov.uk/doc/open-government-licence/version/2/ This work is written by (a) US Government employee(s) and is in the public domain in the US. This Open Access article contains public sector information licensed under the Open Government Licence v2.0 (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/2/). |
spellingShingle | Review Article Gundlapalli, Adi V Salerno, Reynolds M Brooks, John T Averhoff, Francisco Petersen, Lyle R McDonald, L Clifford Iademarco, Michael F SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response |
title | SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response |
title_full | SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response |
title_fullStr | SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response |
title_full_unstemmed | SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response |
title_short | SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response |
title_sort | sars-cov-2 serologic assay needs for the next phase of the us covid-19 pandemic response |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717402/ https://www.ncbi.nlm.nih.gov/pubmed/33442555 http://dx.doi.org/10.1093/ofid/ofaa555 |
work_keys_str_mv | AT gundlapalliadiv sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse AT salernoreynoldsm sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse AT brooksjohnt sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse AT averhofffrancisco sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse AT petersenlyler sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse AT mcdonaldlclifford sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse AT iademarcomichaelf sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse AT sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse |